Gilead Sciences Inc. (NASDAQ:GILD) – Research analysts at Jefferies Group reduced their Q3 2016 earnings per share (EPS) estimates for Gilead Sciences in a report issued on Wednesday. Jefferies Group analyst B. Abrahams now anticipates that the firm will post earnings per share of $2.87 for the quarter, down from their previous estimate of $2.89. Jefferies Group has a “Buy” rating and a $93.00 price objective on the stock. Jefferies Group also issued estimates for Gilead Sciences’ Q4 2016 earnings at $2.79 EPS, FY2016 earnings at $11.66 EPS and FY2017 earnings at $10.76 EPS.

GILD has been the topic of a number of other reports. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday, October 3rd. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Monday, September 26th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $108.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 31st. Leerink Swann set a $112.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $93.97 price objective on the stock in a report on Tuesday, July 26th. Ten research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $104.71.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 75.24 on Thursday. Gilead Sciences has a 12-month low of $74.92 and a 12-month high of $111.11. The stock’s 50 day moving average is $78.95 and its 200 day moving average is $85.05. The stock has a market capitalization of $99.29 billion, a PE ratio of 6.60 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period in the previous year, the company posted $3.15 EPS. Gilead Sciences’s revenue was down 5.7% on a year-over-year basis.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is presently 16.56%.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the sale, the executive vice president now owns 64,122 shares in the company, valued at approximately $5,117,576.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the completion of the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of GILD. CWM LLC boosted its stake in shares of Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 17 shares during the period. Cadence Bank NA boosted its stake in shares of Gilead Sciences by 0.8% in the second quarter. Cadence Bank NA now owns 3,727 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 28 shares during the period. Marble Harbor Investment Counsel LLC boosted its stake in shares of Gilead Sciences by 0.9% in the second quarter. Marble Harbor Investment Counsel LLC now owns 3,330 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 30 shares during the period. Birch Hill Investment Advisors LLC boosted its stake in shares of Gilead Sciences by 0.9% in the second quarter. Birch Hill Investment Advisors LLC now owns 3,336 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 30 shares during the period. Finally, West Oak Capital LLC boosted its stake in shares of Gilead Sciences by 0.7% in the third quarter. West Oak Capital LLC now owns 4,449 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 77.94% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.